Company: SUPN
Filing Date: 2025-06-16
Form Type: SC TO-C
Source: 0001104659-25-059956
Chunk: 2

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-06-16
Form: SC TO-C
Chunk 2
---
 Solicitation/Recommendation Statement and related materials will be filed with the SEC, and Sage investors
and security holders may obtain a free copy of these materials (when available) and other documents filed by Supernus, Purchaser and
Sage with the SEC at the website maintained by the SEC at www.sec.gov. In addition, the Tender Offer Statement and other documents that
Supernus and Purchaser file with the SEC will be made available to all investors and security holders of Sage free of charge from the
information agent for the tender offer. Investors may also obtain, at no charge, the documents filed with or furnished to the SEC by
Supernus under the “Investor Relations” section of Supernus’s website at .

SAGE’S SHAREHOLDERS ARE ADVISED TO READ
THE TENDER OFFER MATERIALS AND THE SOLICITATION/RECOMMENDATION STATEMENT, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND
ANY OTHER RELEVANT DOCUMENTS FILED BY ADAMAS OR SUPERNUS WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT
TO THE TENDER OFFER. THESE MATERIALS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TENDER OFFER, SAGE AND SUPERNUS.

Forward-Looking Statements

This communication includes forward-looking statements.
These statements do not convey historical information but relate to predicted or potential future events that are based upon management's
current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from
those expressed or implied by such statements. In addition to the factors mentioned in this communication, such risks and uncertainties
include, but are not limited to, the risk that the proposed acquisition of Sage by Supernus may not be completed; the possibility that
competing offers or acquisition proposals for Sage will be made; the delay or failure of the tender offer conditions to be satisfied (or
waived), including insufficient shares of Sage common stock being tendered in the tender offer; the failure (or delay) to receive the
required regulatory approvals of the proposed acquisition; the possibility that prior to the completion of the transactions contemplated
by the acquisition agreement, Supernus’ or the Sage’s business may experience significant disruptions due to transaction related
uncertainty; the effects of disruption from the transactions of Sage’s business and the fact that the announcement and pendency
of the transactions may make it more difficult to establish or maintain relationships with employees, manufactures, suppliers, vendors